House Expected To Eliminate Earmarks, give NCI $2 Billion For FY94, A $40 Million Increase
In Brief: Gene Therapy For ADA Deficiency Moves forward With Stem Cell Treatment In Caif. And At NIH
ACS Initiates Cage In Approach to Study Of alternative Methods
DT Board Oks RFAs In Surgery, HIV, Breast Cancer
Patient Costs In Trials Should Be Paid In Any Reform Plan, DCT Board Write To Shalala
FDA Simplifies Reporting Of Adverse Events
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Scaling excellence: How City of Hope is transforming cancer care delivery
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI